Scarica l'app Stockscreener
421.47
3.95%
16.01
Dopo l'orario di chiusura:
422.00
0.53
+0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TMO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$405.46
Aprire:
$406.29
Volume 24 ore:
2.60M
Relative Volume:
1.02
Capitalizzazione di mercato:
$156.49B
Reddito:
$42.90B
Utile/perdita netta:
$6.52B
Rapporto P/E:
24.72
EPS:
17.05
Flusso di cassa netto:
$6.72B
1 W Prestazione:
+4.23%
1M Prestazione:
+4.63%
6M Prestazione:
-18.98%
1 anno Prestazione:
-22.20%
Intervallo 1D:
$404.85
$429.10
Intervallo di 1 settimana:
$398.08
$429.10
Portata 52W:
$385.46
$627.88
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Nome
Thermo Fisher Scientific Inc
Settore
Industria
Telefono
(781) 622-1000
Indirizzo
168 THIRD AVENUE, WALTHAM, MA
Confronta TMO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
421.47 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
201.10 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
542.65 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
120.45 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
162.61 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-01 | Iniziato | Stephens | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-03-18 | Ripresa | Citigroup | Neutral |
| 2024-01-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-26 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-06 | Ripresa | Citigroup | Buy |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-07-19 | Reiterato | Robert W. Baird | Outperform |
| 2023-07-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Reiterato | Barclays | Overweight |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-27 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-04-25 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Ripresa | Barclays | Overweight |
| 2021-10-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-16 | Iniziato | The Benchmark Company | Buy |
| 2021-03-18 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Iniziato | Barclays | Overweight |
| 2021-01-08 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Iniziato | Goldman | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-14 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-20 | Ripresa | JP Morgan | Overweight |
| 2020-07-15 | Aggiornamento | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Reiterato | Needham | Buy |
| 2020-04-23 | Reiterato | Needham | Buy |
| 2020-01-31 | Reiterato | Needham | Buy |
| 2020-01-22 | Iniziato | Credit Suisse | Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-07-25 | Reiterato | Needham | Buy |
| 2019-07-16 | Downgrade | Needham | Strong Buy → Buy |
| 2019-05-30 | Iniziato | Wolfe Research | Outperform |
| 2019-05-23 | Reiterato | Needham | Strong Buy |
| 2019-04-22 | Reiterato | Needham | Strong Buy |
| 2019-04-16 | Reiterato | BofA/Merrill | Buy |
Mostra tutto
Thermo Fisher Scientific Inc Borsa (TMO) Ultime notizie
Hyderabad-based CCMB, Thermo Fisher Scientific launch supply centre, aims at strengthening research in life sciences - Telangana Today
Thermo Fisher Scientific Inc. stock falls Tuesday, underperforms market - MSN
Thermo Fisher’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Thermo Fisher stock hits 52-week low at $390.45 - Investing.com
Thermo Fisher stock hits 52-week low at $390.45 By Investing.com - Investing.com South Africa
Thermo Fisher Scientific’s SWOT analysis: stock outlook amid acquisitions, tariffs - Investing.com
Thermo Fisher Scientific Unveils New Mass Spectrometers to Advance Scientific Discovery - Insider Monkey
Thermo Fisher Scientific introduces the next generation Thermo Scientific™ Vanquish™ Charged Aerosol Detector P Series for more sensitive detection of impurities - bio-itworld.com
Thermo Fisher Scientific (TMO) Opinions on Diagnostics Division Sale - Nasdaq
Thermo Fisher Scientific Could Divest Diagnostics Division for More than $4B - Medical Device and Diagnostic industry
Flow Cytometer | Thermo Fisher Scientific Inc. | Jun 2025 - Photonics Spectra
Thermo Fisher Scientific Awarded $94M Navy Occupational Dosimetry System Contract - ExecutiveBiz
Tufts Center Study Shows Significant Time Savings in Delivering Therapies to Patients with Thermo Fisher Scientific’s Accelerator™ Drug Development 360° CDMO and CRO Solutions - Business Wire
Ethris and Thermo Fisher partner on mRNA solutions - Yahoo Finance
Bioreactor Market Insights 2025-2033 | Leading Vendors: Thermo Fisher Scientific, GE Healthcare, Sartorius - openPR.com
Thermo Fisher (TMO) Eyes Future Growth with Strategic mRNA Deal and Acquisition - Daily Chhattisgarh News
Next-Gen Diagnostics Drive Biochips Market Growth: Thermo Fisher, Illumina, and PerkinElmer at the Forefront - openPR.com
Report: Biotech Research Firm Thermo Fisher Considers Selling Diagnostics Business - PYMNTS.com
Thermo Fisher Scientific Explores Diagnostics Exit Amid mRNA Expansion S&P 500 - Kalkine Media
Thermo Fisher Scientific (NYSE:TMO) Explores US$4 Billion Diagnostics Sale, Expands mRNA Collaboration - simplywall.st
Thermo Fisher Stock Hurt by Macroeconomic Woes, Tough Competition - MSN
Ethris and Thermo Fisher Partner to Streamline mRNA Therapeutics Development - BioPharm International
October 17th Options Now Available For Thermo Fisher Scientific (TMO) - Nasdaq
High Frequency Electrocautery Market Deep Research Report with - openPR.com
Deals of the day-Mergers and acquisitions - marketscreener.com
Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms - Business Wire
Thermo Fisher said to weigh sale of some diagnostic assets for $4B - MSN
Thermo Fisher (TMO) Plans $4 Billion Sale of Diagnostics Divisio - GuruFocus
Thermo Fisher (TMO) Considers $4B Sale of Diagnostic Assets - GuruFocus
Thermo Fisher Reportedly Plans to Sell Parts of Diagnostics Unit for $4 Billion - marketscreener.com
Thermo Fisher plans to sell parts of diagnostics unit for $4 billion, FT reports - ET HealthWorld
Thermo Fisher plans to sell parts of diagnostics unit for $4 billion, FT reports By Reuters - Investing.com
Thermo Fisher Plans to Sell Parts of Diagnostics Unit for $4 Billion, FT Reports - US News Money
Thermo Fisher aims to sell parts of its diagnostics business for $4 billion, FT reports - TradingView
Thermo Fisher aims to sell parts of its diagnostics business for $4bn - Financial Times
Thermo Fisher (TMO) Stock Shows Signs of Rebound After Challenging Year - Daily Chhattisgarh News
Plasmid Purification Market Exclusive Report with Detailed - openPR.com
Regeneron Genetics Center Selects Olink® Explore HT for Landmark Proteomics Study of 200,000 Patient Samples - Business Wire
APJ, EEMEA and LATAM Thermo Scientific AST plate guide - SelectScience
Brain Cancer Diagnostics Market Key Players AnalysisThermo - openPR.com
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.
Thermo Fisher (TMO) Closes with Minor Gains After Volatile Session, Stock Still Down Significantly for the Year - Daily Chhattisgarh News
Ex-Dividend Reminder: Gilead Sciences, CONMED and Thermo Fisher Scientific - Nasdaq
HSBC Adjusts Price Target on Thermo Fisher Scientific to $560 From $590 - marketscreener.com
Thermo Fisher Scientific highlights case for combining electron microscopy and microtomography - Metal Additive Manufacturing magazine
Thermo Fisher (TMO) Rallies Over 1%, But Still Faces Long-Term Headwinds - Daily Chhattisgarh News
$100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth This Much Today - Benzinga
Thermo Scientific Precis Methods - SelectScience
Thermo Scientific SureTect automation workflow - SelectScience
Thermo Fisher Cuts Annual Profit Outlook Amid Estimated $400M Tariff Hit - insights.citeline.com
Old National Bancorp Reduces Stake in Thermo Fisher Scientific - Zenopa
Thermo Fisher Scientific Inc Azioni (TMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):